<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525147</url>
  </required_header>
  <id_info>
    <org_study_id>YHB1411-2-101</org_study_id>
    <nct_id>NCT01525147</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers</brief_title>
  <official_title>A Block-randomized, Double-blind, Placebo-controlled, Single-dose Escalating, Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A block-randomized, double-blind, placebo-controlled, single-dose escalating, phase I
      clinical trial to evaluate the safety, tolerability and pharmacokinetics of YHB1411-2 in
      healthy male volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First in human Study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Evaluation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay(an expected average of 1 week) and out-patient visit for 8 weeks → Specified timepoints in the protocol.</time_frame>
    <description>Adverse Events, Physical examination, ECG, Vital sign, Clinical Laboratory Tests results, Chest X-ray</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Evaluation</measure>
    <time_frame>PK sampling : participants will be followed for the duration of hospital stay(an expected average of 1 week) and out-patient visit for 8 weeks → Specified timepoints in the protocol.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Evaluation</measure>
    <time_frame>HAHA measurement(blood sampling): pre-dose and out-patient visit for 8 weeks → Specified timepoints in the protocol.</time_frame>
    <description>HAHA (Human anti human antibodies) measurement
Neutralizing Antibody measurement: only if antibody formation has verified</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Rheumatic Arthritis</condition>
  <arm_group>
    <arm_group_label>YHB1411-2: Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YHB1411-2: Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ratio of Test Drug(YHB1411-2) to Placebo is 13 :2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YHB1411-2: Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YHB1411-2: Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YHB1411-2: Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All investigational products are YHB1411-2(This level is pilot study).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>YHB1411-2: Level 2</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>YHB1411-2: Level 2</arm_group_label>
    <other_name>Undecided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>YHB1411-2: Level 3</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>YHB1411-2: Level 3</arm_group_label>
    <other_name>Undecided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>YHB1411-2: Level 4</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>YHB1411-2: Level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>YHB1411-2: Level 5</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>YHB1411-2: Level 5</arm_group_label>
    <other_name>Undecided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>YHB1411-2: Level 2</arm_group_label>
    <arm_group_label>YHB1411-2: Level 3</arm_group_label>
    <arm_group_label>YHB1411-2: Level 4</arm_group_label>
    <arm_group_label>YHB1411-2: Level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>YHB1411-2: level 1</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>YHB1411-2: Level 1</arm_group_label>
    <other_name>Undecided</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers of aged between 20 to 45 years old at the time of screening

          2. Volunteers weighing over 50 kg with body mass index between 18.0 ~ 28.0 kg/m2

          3. Volunteers who has signed a written informed consent voluntarily, prior to any
             procedure, using a form that is approved by the local Institutional Review Board after
             detail explanation of the purpose, contents, and characteristic of the drug

        Exclusion Criteria:

          1. Have history or presence of clinically significant diseases in liver, kidney,
             gastrointestinal tract, nervous system, respiratory system, endocrine system,
             blood•tumor, cardiovascular, urinary system, and mental disorder

          2. Presence of current tuberculosis or latent tuberculosis or have history of
             tuberculosis (confirmed by chest X-ray test or tuberculin skin test)

          3. Have active infection such as chronic or topical infection

          4. Have history of hospitalization or have received antibiotics due to serious infection
             within 1 month prior to the first administration

          5. Have know hypersensitivity to biologicals

          6. Have AST(SGOT) or/and ALT(SGPT) &gt; 1.5 times of normal upper limit at the time of
             screening

          7. Shown positive results in any of HBsAg, HCV Ab, HIV Ab tests

          8. Have history of drug abuse or shown positive reaction of drug abuse in urine test at
             the time of screening

          9. Received any biological drugs including monoclonal antibody products or protein drugs
             within the last 6 months prior to the first administration

         10. Participated in any other clinical trials within 2 months prior to the first
             administration of Investigational Product

         11. Have donated whole blood within 2 months prior to the first administration of
             Investigational Product, or donated blood components or received transfusion within 1
             month prior to the first administration of Investigational Product

         12. Subject who drink continuously (over 21 units/week, 1 unit = 10 g of pure alcohol) or
             who cannot quit drinking while hospitalized

         13. Smoker (Subject can be enrolled if he/she had quit smoking within 3 months before the
             first administration of Investigational Product (Day 1))

         14. Subject who is judged to be ineligible by principal investigator or sub-investigator
             according to various reasons including their abnormal test results (clinical
             laboratory test, chest X-ray test, 12-lead ECG)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo-Seung Huh, MD,PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Irwon-dong, Gangnam-gu</state>
        <zip>130-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

